Compass Therapeutics (NASDAQ:CMPX) Hits New 1-Year High – Still a Buy?

Compass Therapeutics, Inc. (NASDAQ:CMPX)’s stock price reached a new 52-week high during trading on Thursday . The stock traded as high as $6.32 and last traded at $6.3450, with a volume of 1426515 shares changing hands. The stock had previously closed at $5.90.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. Wall Street Zen lowered shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 17th. William Blair initiated coverage on Compass Therapeutics in a report on Monday, January 5th. They issued an “outperform” rating on the stock. Citigroup initiated coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They set an “outperform” rating for the company. Citizens Jmp initiated coverage on Compass Therapeutics in a research note on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 target price on the stock. Finally, Lifesci Capital initiated coverage on shares of Compass Therapeutics in a report on Monday, October 6th. They issued an “outperform” rating and a $10.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $12.23.

Compass Therapeutics Stock Up 7.4%

The company has a market capitalization of $1.13 billion, a PE ratio of -14.07 and a beta of 1.45. The business has a 50 day simple moving average of $5.26 and a 200 day simple moving average of $4.10.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.06. Equities analysts expect that Compass Therapeutics, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Investors Weigh In On Compass Therapeutics

Large investors have recently made changes to their positions in the stock. Vivo Capital LLC increased its holdings in shares of Compass Therapeutics by 70.0% in the second quarter. Vivo Capital LLC now owns 6,043,466 shares of the company’s stock valued at $15,713,000 after purchasing an additional 2,487,443 shares during the period. Simplicity Wealth LLC increased its holdings in Compass Therapeutics by 81.8% in the 2nd quarter. Simplicity Wealth LLC now owns 84,636 shares of the company’s stock worth $220,000 after buying an additional 38,093 shares during the period. Avanza Fonder AB purchased a new position in Compass Therapeutics during the 4th quarter worth approximately $147,000. Caxton Corp raised its position in Compass Therapeutics by 23.1% during the 3rd quarter. Caxton Corp now owns 53,503 shares of the company’s stock worth $187,000 after buying an additional 10,038 shares during the last quarter. Finally, Suvretta Capital Management LLC lifted its stake in Compass Therapeutics by 97.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock valued at $49,354,000 after acquiring an additional 6,951,666 shares during the period. 68.43% of the stock is owned by hedge funds and other institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.